Involvement of the fractalkine pathway in the pathogenesis of childhood hemolytic uremic syndrome

Blood

Volumn 109, Issue 6, 2007, Pages 2438-2445

  Ramos, María Victoria ^a   Fernández, Gabriela C ^a   Patey, Natasha ^d   Schierloh, Pablo ^a   Exeni, Ramón ^b   Grimoldi, Irene ^b   Vallejo, Graciela ^c   Elías Costa, Christian ^c   Sasiain, Maria Del Carmen ^a   Trachtman, Howard ^g   Combadière, Christophe ^f   Proulx, François ^e   Palermo, Marina S ^a  

^a ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^b Hospital Municipal Del Niño   (Argentina)

^c HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e UNIVERSITY OF MONTREAL   (Canada)

^f INSERM   (France)

^g SCHNEIDER CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; FRACTALKINE; MEMBRANE PROTEIN; PROTEIN CX3CR1; UNCLASSIFIED DRUG;

ARTICLE; CELL SUBPOPULATION; CHILD; CIRCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY FAILURE; MALE; MONONUCLEAR CELL; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION;

EID: 33947281815     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-06-026997     Document Type: Article

References (59)

1. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis. 1985;151:775-782.
2. Remuzzi G, Ruggenenti P.The hemolytic uremic syndrome. Kidney Int. 1995;48:2-19.
3. Paton JC, Paton AW.Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev. 1998;11:450-479.
4. Keusch GT, Acheson DW. Thrombotic thrombocytopenic purpura associated with Shiga toxins. Semin Hematol. 1997;34;106-116.
5. Stahl AL, Svensson M, Morgelin M, et al. Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets via TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome. Blood. 2006;108:167-176.
6. Harrison LM, van den Hoogen C, van Haaften WC, Tesh VL. Chemokine expression in the monocytic cell line THP-1 in response to purified shiga toxin 1 and/or lipopolysaccharides. Infect Immun. 2005;73:403-412.
7. Guessous F, Marcinkiewicz M, Polanowska-Grabowska R, Keepers TR, Obrig T, Gear AR. Shiga toxin 2 and lipopolysaccharide cause monocytic THP-1 cells to release factors which activate platelet function. Thromb Haemost. 2005;94:1019-1027.
8. Proulx F, Toledano B, Phan V, Clermont MJ, Mariscalco MM, Seidman EG. Circulating granulocyte colony-stimulating factor, C-X-C, and C-C chemokines in children with Escherichia coli O157:H7 associated hemolytic uremic syndrome. Pediatr Res. 2002;52:928-934.
9. Palermo MS, Alves Rosa MF, Van Rooijen N, Isturiz MA. Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model. Clin Exp Immunol. 1999;116:462-467.
10. Meerschaert J, Furie MB. The adhesion molecules used by monocytes for migration across endothelium include CD11a/CD18, CD11b/CD18, and VLA-4 on monocytes and ICAM-1, VCAM-1, and other ligands on endothelium. J Immunol. 1995;154:4099-4112.
11. Patarroyo M. Adhesion molecules mediating recruitment of monocytes to inflamed tissue. Immunobiology. 1994;191:474-477.
12. Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O, Imai T. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol. 2004;24:34-40.
13. Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385:640-644.
14. Imai T, Hieshima K, Haskell C, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997;91:521-530.
15. 3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med. 1998;188:1413-1419.
16. Beck GC, Yard BA, Breedijk AJ, Van Ackern K, Van Der Woude FJ. Release of CXC-chemokines by human lung microvascular endothelial cells (LMVEC) compared with macrovascular umbilical vein endothelial cells. Clin Exp Immunol. 1999;118:298-303.
17. Chakravorty SJ, Cockwell P, Girdlestone J, Brooks CJ, Savage CO. Fractalkine expression on human renal tubular epithelial cells: potential role in mononuclear cell adhesion. Clin Exp Immunol. 2002;129:150-159.
18. Muehlhoefer A, Saubermann LJ, Gu X, et al. Fractalkine is an epithelial and endothelial cellderived chemoattractant for intraepithelial lymphocytes in the small intestinal.mucosa. J Immunol. 2000;164:3368-3376.
19. Umehara H, Bloom E, Okazaki T, Domae N, Imai T. Fractalkine and vascular injury. Trends Immunol. 2001;22:602-607.
20. Yoneda O, Imai T, Nishimura M, et al. Membrane-bound form of fractalkine induces IFN-gamma production by NK cells. Eur J Immunol. 2003;33:53-58.
21. Papadopoulos EJ, Sassetti C, Saeki H, et al. Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is up-regulated upon dendritic cell maturation. Eur J Immunol. 1999;29:2551-2559.
22. Dichmann S, Herouy Y, Purlis D, Rheinen H, Gebicke-Harter P, Norgauer J. Fractalkine induces chemotaxis and actin polymerization in human dendritic cells. Inflamm Res. 2001;50:529-533.
23. Haskell CA, Cleary MD, Charo IF. Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of Gprotein activation. J Biol Chem. 1999;274:10053-10058.
24. Goda S, Imai T, Yoshie O, et al. CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J Immunol. 2000;164:4313-4320.
25. 3CR1 rapid communication. Kidney Int. 1999;56:612-620.
26. Chen S, Bacon KB, Li L, et al. In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II. J Exp Med. 1998;188:193-198.
27. 3CR1) in human kidney diseases. Kidney Int. 2002;62:488-495.
28. Ito Y, Kawachi H, Morioka Y, et al. Fractalkine expression and the recruitment of CX3CR1+ cells in the prolonged mesangial proliferative glomerulonephritis. Kidney Int. 2002;61:2044-2057.
29. Boyum A. Separation of leukocytes from blood and bone marrow: introduction. Scand J Clin Lab Invest Suppl. 1968;97:7.
30. Ziegler-Heitbrock HW. Heterogeneity of human blood monocytes: the CD14+ CD16+ subpopulation. Immunol Today. 1996;17:424-428.
31. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003;19:71-82.
32. Ziegler-Heitbrock HW. Definition of human blood monocytes. J Leukoc Biol. 2000;67:603-606.
33. Frey M, Packianathan NB, Fehniger TA, et al. Differential expression and function of L-selectin on CD56bright and CD56dim Natural Killer subsets. J Immunol. 1998;161:400-408.
34. + NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol. 2001; 166:6477-6482.
35. bright cells in tuberculous pleurisy. J Immunol. 2005;175:6852-6860.
36. Gianantonio CA, Vitaco M, Mendilaharzu F, Gallo GE, Sojo ET. The hemolytic-uremic s?́ndrome. Nephron. 1973;11:174-192.
37. Fernandez GC, Ramos MV, Gomez SA, et al. Differential expression of function-related antigens on blood monocytes in children with hemolytic uremic syndrome. J Leukoc Biol. 2005;78:853-861.
38. ++ cells derived in vitro from peripheral blood monocytes exhibit phenotypic and functional dendritic cell-like characteristics. Eur J Immunol. 2000;30:1872-1883.
39. Olikowsky T, Wang ZQ, Dudhane A, Horowitz H, Conti B, Hoffmann MK Two distinct pathways of human macrophage differentiation are mediated by interferon-gamma and interleukin-10. Immunology. 1997;91:104-108.
40. Kishimoto TK, Jutila MA, Butcher EC. Identification of a human peripheral lymph node homing receptor: a rapidly down-regulated adhesion molecule. Proc Natl Acad Sci U S A. 1990;87:2244-2248.
41. Tedder TF, Steeber DA, Pizcueta P. L-selectin-deficient mice have impaired leukocyte recruitment into inflammatory sites. J Exp Med. 1995;181:2259-2264.
42. Chen A, Engel P, Tedder TF. Structural requirements regulate endoproteolytic release of the L-selectin (CD62L) adhesion receptor from the cell surface of leukocytes. J Exp Med. 1995;182:519-530.
43. Dadfar E, Lundahl J, Jacobson SH. Monocyte adhesion molecule expression in interstitial inflammation in patients with renal failure. Nephrol Dial Transplant. 2004;19:614-622.
44. Chapman GA, Moores KE, Gohil J, et al. The role of fractalkine in the recruitment of monocytes to the endothelium. Eur J Pharmacol. 2000;392:189-195.
45. + monocytes. J Exp Med. 2003;197:1701-1707.
46. Salvo G, Samoggia P, Masciulli R, et al. Interleukin-2 bolus therapy induces immediate and selective disappearance from peripheral blood of all lymphocyte subpopulations displaying natural killer activity: role of cell adhesion to endothelium. Eur J Cancer. 1992;28A:818-825.
47. Aronson FR, Libby P, Brandon EP, Janicka MW, Mier JW. IL-2 rapidly induces natural killer cell adhesion to human endothelial cells: a potential mechanism for endothelial injury. J Immunol. 1988;141:158-163.
48. Lentsch AB, Miller FN, Edwards MJ. Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2. Cancer Immunol Immunother. 1999;47:243-248.
49. Alexandrescu DT, Maddukuri P, Wiernik PH, Dutcher JP. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome associated with high-dose interleukin-2 for the treatment of metastatic melanoma. J Immunother. 2005;28:144-147.
50. Lanier LL. Face off: the interplay between activating and inhibitory immune receptors. Curr Opin Immunol. 2001;13:326-31.
51. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005;365:1073-1086.
52. Chandler WL, Jelacic S, Boster DR, et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med. 2002;346:23-32.
53. Harrison JK, Jiang Y, Wees EA, et al. Inflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heart. J Leukoc Biol. 1999:66:937-944.
54. Imaizumi T, Yoshida H, Satoh K. Regulation of CX3CL1/fractalkine expression in endothelial. cells. J Atheroscler Thromb. 2004;11:15-21.
55. Litalien C, Proulx F, Mariscalco MM, et al. Circulating inflammatory cytokine levels predict severity of renal failure in hemolytic uremic syndrome. Pediatr Nephrol. 1999;13:840-845.
56. Westerholt S, Pieper AK, Griebel M, Volk HD, Hartung T, Oberhoffer R. Characterization of the cytokine immune response in children who have experienced an episode of typical hemolytic-uremic syndrome. Clin Diagn Lab Immunol. 2003;10:1090-1095.
57. 3CR1) as an amplification circuit of polarized Th1 responses. J. Clin Invest. 2001;107:1173-1181.
58. 3CR1. Blood. 2003;102:3494-3503.
59. 3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients. FASEB J. 2005;19:1902-1904.